No Data
No Data
Liaoning Chengda Biotechnology Co.,Ltd.'s (SHSE:688739) Business Is Trailing The Market But Its Shares Aren't
2024 Semi-Annual Report of Liaoning Chengda Biology Co., Ltd.
Summary of the 2024 semi-annual report of Liaoning Chengda Biology Co., Ltd.
Chengda Biotech (688739.SH): The net income in the first half of the year was 0.22 billion yuan, a year-on-year decrease of 33.99%.
Gelonghui, August 29th, Chendasheng Bio(688739.SH) disclosed the semi-annual report for the year 2024. During the reporting period, the company achieved a revenue of 0.881 billion yuan, a year-on-year increase of 1.08%; net income attributable to the parent company was 0.22 billion yuan, a year-on-year decrease of 33.99%; non-GAAP net income was 0.211 billion yuan, a year-on-year decrease of 31.86%; basic earnings per share was 0.53 yuan.
Chengdu Sincerity Bio (688739.SH) released its semi-annual performance, with a net income of 0.22 billion yuan, a year-on-year decrease of 33.99%.
Chengdu Bio (688739.SH) disclosed its 2024 interim report, reporting that the company achieved a revenue of 8.81...
Chengda Biotech(688739.SH): Completed the share buyback, actually repurchasing 1.8323 million shares of the company's shares.
On July 18th, Gelunhui reported that Chengda Biotech (688739.SH) has completed the repurchase of shares, and actually repurchased 1.8323 million shares of the company, accounting for 0.44% of the total share capital of the company. The maximum repurchase price was 28.15 yuan/share, the minimum repurchase price was 24.22 yuan/share, the average repurchase price was 27.285 yuan/share, and the total repurchase funds were 49.9933 million yuan (excluding transaction commissions and other transaction fees) as of the disclosure date of this announcement.
No Data